This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

A timeless Mediterranean home merges history, family legacy, and modern functionality in Sežana, Slovenia. Nestled in the ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS ...

The product recommendations in this post are recommendations by the writer and/or expert(s) interviewed and do not contain affiliate links. Meaning: If you use these links to buy something, we will ...

This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." The CodeBreaK 300 clinical trial compared ...

GuruFocus has detected 6 Warning Signs with AMGN. The decision, announced Thursday, applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300 ...

NEW YORK – The US Food and Drug Administration on Thursday approved Amgen's KRAS inhibitor Lumakras (sotorasib) with its EGFR monoclonal antibody Vectibix (panitumumab) for previously treated patients ...

The craft supplies and fabric retailer Joann filed for bankruptcy for the second time in less than a year, as the chain wrestles with declining sales and inventory shortages, the company said ...